| 1 |
35194903 | XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA. | 2022 May |
2 |
| 2 |
31669203 | PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers. | 2020 Jan 28 |
1 |
| 3 |
33425022 | XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. | 2020 |
1 |
| 4 |
27559053 | Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors. | 2017 Feb 15 |
1 |
| 5 |
24770870 | Base excision repair defects invoke hypersensitivity to PARP inhibition. | 2014 Aug |
1 |